Rodney Lappe Biography and Net Worth

Director of Design Therapeutics

Rodney Lappe, Ph.D., has had a distinguished career as a biopharmaceutical scientist and executive. Most recently, Dr. Lappe served as executive chairman of the board of directors for Mirati Therapeutics (MRTX), a role he had served at until he resigned in February 2019, after becoming a member of the board in June 2012 and chairman of the board in July 2013. Previously, Dr. Lappe was group senior vice president, Pfizer Worldwide Research and Development and chief scientific officer for CovX in San Diego. Dr. Lappe has also served as vice president for cardiovascular and metabolic diseases at Pharmacia where he was also site leader for Pharmacia in St. Louis. Prior to joining Pharmacia, he held positions with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his B.A. from Blackburn College and his Ph.D. in pharmacology from Indiana University.

What is Rodney W. Lappe's net worth?: The estimated net worth of Rodney W. Lappe is at least $1.31 million as of September 29th, 2023. Dr. Lappe owns 133,024 shares of Design Therapeutics stock worth more than $1,306,296 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Lappe may own. Learn More about Rodney W. Lappe's net worth.
How do I contact Rodney W. Lappe?: The corporate mailing address for Dr. Lappe and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on Rodney W. Lappe's contact information.
Has Rodney W. Lappe been buying or selling shares of Design Therapeutics?: Rodney W. Lappe has not been actively trading shares of Design Therapeutics over the course of the past ninety days. Most recently, on Friday, September 29th, Rodney W. Lappe bought 21,000 shares of Design Therapeutics stock. The stock was acquired at an average cost of $2.35 per share, with a total value of $49,350.00. Following the completion of the transaction, the director now directly owns 133,024 shares of the company's stock, valued at $312,606.40. Learn More on Rodney W. Lappe's trading history.
Who are Design Therapeutics' active insiders?: Design Therapeutics' insider roster includes Rodney Lappe (Director), Deepa Prasad (Director), John Schmid (Director), and Arsani William (Director). Learn More on Design Therapeutics' active insiders.
Are insiders buying or selling shares of Design Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 3,806 shares worth more than $23,863.62. The most recent insider tranaction occured on December, 18th when Director Deepa Prasad sold 3,806 shares worth more than $23,863.62. Insiders at Design Therapeutics own 23.5% of the company. Learn More about insider trades at Design Therapeutics.
Information on this page was last updated on 12/18/2024.

Rodney W. Lappe Insider Trading History at Design Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/29/2023	Buy	21,000	$2.35	$49,350.00	133,024
12/9/2022	Buy	15,000	$7.96	$119,400.00	112,024

Rodney W. Lappe Buying and Selling Activity at Design Therapeutics

Design Therapeutics Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $9.82

$9.33

$10.02

50 Day Range

MA: $7.21

$5.53

$9.82

2 Week Range

Now: $9.82

$2.60

$10.02

Volume

320,153 shs

Average Volume

514,527 shs

Market Capitalization

$559.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63